Fluorine in PDB 5lz7: Fragment-Based Inhibitors of Lipoprotein Associated Phospholipase A2

Enzymatic activity of Fragment-Based Inhibitors of Lipoprotein Associated Phospholipase A2

All present enzymatic activity of Fragment-Based Inhibitors of Lipoprotein Associated Phospholipase A2:
3.1.1.47;

Protein crystallography data

The structure of Fragment-Based Inhibitors of Lipoprotein Associated Phospholipase A2, PDB code: 5lz7 was solved by A.Woolford, P.Day, with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:

*Resolution Low / High (Å)*	32.99 / 2.10
*Space group*	C 1 2 1
*Cell size a, b, c (Å), α, β, γ (°)*	99.623, 91.456, 51.413, 90.00, 112.11, 90.00
*R / R_free (%)*	18 / 24.3

Other elements in 5lz7:

The structure of Fragment-Based Inhibitors of Lipoprotein Associated Phospholipase A2 also contains other interesting chemical elements:

Chlorine

(Cl)

1 atom

Fluorine Binding Sites:

The binding sites of Fluorine atom in the Fragment-Based Inhibitors of Lipoprotein Associated Phospholipase A2 (pdb code 5lz7). This binding sites where shown within 5.0 Angstroms radius around Fluorine atom.
In total only one binding site of Fluorine was determined in the Fragment-Based Inhibitors of Lipoprotein Associated Phospholipase A2, PDB code: 5lz7:

Fluorine binding site 1 out of 1 in 5lz7

Go back to

Fluorine Binding Sites List in 5lz7

Fluorine binding site 1 out of 1 in the Fragment-Based Inhibitors of Lipoprotein Associated Phospholipase A2

Mono view

Stereo pair view

A full contact list of Fluorine with other atoms in the F binding site number 1 of Fragment-Based Inhibitors of Lipoprotein Associated Phospholipase A2 within 5.0Å range:

probe	atom	residue	distance (Å)	B	Occ
A:F502 b:24.3 occ:0.79	F12	A:7BK502	0.0	24.3	0.8
	C11	A:7BK502	1.4	26.2	0.8
	C10	A:7BK502	2.4	25.2	0.8
	C13	A:7BK502	2.4	23.1	0.8
	H36	A:7BK502	2.5	25.1	0.8
	C14	A:7BK502	2.8	21.5	0.8
	CD1	A:LEU159	3.2	29.5	1.0
	CD2	A:LEU107	3.3	36.0	1.0
	N15	A:7BK502	3.5	19.4	0.8
	C9	A:7BK502	3.6	24.7	0.8
	C16	A:7BK502	3.6	23.8	0.8
	O	A:HOH916	3.8	33.9	0.5
	CD2	A:PHE357	3.8	31.2	1.0
	CE2	A:PHE357	4.0	32.6	1.0
	C8	A:7BK502	4.1	24.5	0.8
	O	A:GLY154	4.1	33.7	1.0
	H35	A:7BK502	4.4	24.6	0.8
	H37	A:7BK502	4.4	23.8	0.8
	CA	A:ALA155	4.5	27.0	1.0
	CG	A:LEU159	4.6	31.2	1.0
	CG	A:LEU107	4.6	35.8	1.0
	CB	A:ALA155	4.8	26.2	1.0
	CD1	A:LEU107	4.8	35.8	1.0
	C	A:GLY154	4.8	32.1	1.0
	CG	A:PHE357	4.9	30.9	1.0
	O	A:HOH926	4.9	29.5	0.5
	N	A:ALA155	5.0	29.6	1.0

Reference:

A.J.Woolford, P.J.Day, V.Beneton, V.Berdini, J.E.Coyle, Y.Dudit, P.Grondin, P.Huet, L.Y.Lee, E.S.Manas, R.L.Mcmenamin, C.W.Murray, L.W.Page, V.K.Patel, F.Potvain, S.J.Rich, Y.Sang, D.O.Somers, L.Trottet, Z.Wan, X.Zhang. Fragment-Based Approach to the Development of An Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2). J. Med. Chem. V. 59 10738 2016.
ISSN: ISSN 1520-4804
PubMed: 27933945
DOI: 10.1021/ACS.JMEDCHEM.6B01427

Page generated: Tue Jul 15 05:10:26 2025

Last articles

Mg in 1W0H
Mg in 1VZM
Mg in 1VZK
Mg in 1VZ0
Mg in 1VTY
Mg in 1VTN
Mg in 1VST
Mg in 1VSD
Mg in 1VS0
Mg in 1VRT

	© Copyright 2008-2020 by atomistry.com
Home \| Site Map \| Copyright \| Contact us \| Privacy